PT-141[Bremelanotide, Vyleesi]
Compound snapshot
Class
Melanocortin receptor agonist (bremelanotide)
FDA approved
Yes — bremelanotide (Vyleesi) is approved for hypoactive sexual desire disorder in premenopausal women
Clinical development
Approved
Last reviewed
September 2026
Research areas
Cognition / Mood / Neuroprotection
Regulatory status
FDA-approved medicine
Internet attention
High
Registry query
PT-141
A melanocortin receptor agonist and the approved treatment for hypoactive sexual desire disorder in premenopausal women.
Reality check — what we actually know
Supported by human evidence
- This compound has completed human trials in at least one approved indication — see the regulatory section for what was actually approved.
Animal research only
- Statistically significant increases in desire and reduction in distress in the RECONNECT Phase 3 trials
- Works centrally, so it is effective where vascular drugs are not
- On-demand dosing rather than daily use
Mechanistically plausible
- Acts centrally on MC3R and MC4R in the hypothalamus to increase sexual desire — a brain pathway, not a blood-flow pathway like PDE5 inhibitors.
Common internet claims
- Online discussion frequently presents PT-141 as a proven treatment rather than a research compound.
Not established
- Human efficacy for the outcomes commonly claimed
- Optimal route, quantity and duration in humans
- Long-term human safety
Evidence distribution
Each band is a live PubMed search for PT-141, filtered to that kind of study. Top is the strongest evidence; the base is reasoning, not proof. A band with no records means that kind of study has not been published for this compound yet.
Mechanism and reported findings
Acts centrally on MC3R and MC4R in the hypothalamus to increase sexual desire — a brain pathway, not a blood-flow pathway like PDE5 inhibitors.
- Statistically significant increases in desire and reduction in distress in the RECONNECT Phase 3 trials
- Works centrally, so it is effective where vascular drugs are not
- On-demand dosing rather than daily use
Strength of the evidence: FDA-approved on the strength of two randomised Phase 3 trials.
Safety and known cautions
Nausea is common (about 40% in trials), plus flushing, headache and transient blood-pressure rise. Prescription-only; not for people with uncontrolled hypertension or cardiovascular disease.
Evidence at a glance
No single score, on purpose. The line beside each bar shows how much reported outcomes vary between studies.
Development stage
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- Regulatory review
- ApprovedCurrent